drugset
drugset / Trial / NCT00135421

Study of BMS-562086 in the Treatment of Outpatients With Major Depressive Disorder

NCT00135421 ↗

Phase 1/2 Completed 271 enrolled Bristol-Myers Squibb
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this clinical research study is to learn whether BMS-562086 is both safe and effective in treating outpatients with major depressive disorder.

Timeline

Start
2005-11
Primary completion
2007-10
Completion
2007-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Escitalopram Small molecule 20 mg Oral
Subject Pexacerfont Small molecule 100 mg Oral

Indications

major depressive disorder